BR9908610A - Composto, processo para produzir o mesmo, composição farmacêutica, uso do composto, processos par ainibir a produção de óxido nìtrico e/ou citocina em mamìferos, e para impedir ou tratar doença cardìaca, doença autoimune ou choque séptico em mamìferos, e, pró medicamentos - Google Patents

Composto, processo para produzir o mesmo, composição farmacêutica, uso do composto, processos par ainibir a produção de óxido nìtrico e/ou citocina em mamìferos, e para impedir ou tratar doença cardìaca, doença autoimune ou choque séptico em mamìferos, e, pró medicamentos

Info

Publication number
BR9908610A
BR9908610A BR9908610-7A BR9908610A BR9908610A BR 9908610 A BR9908610 A BR 9908610A BR 9908610 A BR9908610 A BR 9908610A BR 9908610 A BR9908610 A BR 9908610A
Authority
BR
Brazil
Prior art keywords
compound
mammals
optionally
hydrocarbon group
substituents
Prior art date
Application number
BR9908610-7A
Other languages
English (en)
Inventor
Yuzo Ichimori
Ii Masayuki
Katsumi Itoh
Tomoyuki Kitazaki
Junji Yamada
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of BR9908610A publication Critical patent/BR9908610A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/14—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Silicon Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

"COMPOSTO, PROCESSO PARA PRODUZIR O MESMO, COMPOSIçãO FARMACêUTICA, USO DO COMPOSTO, PROCESSOS PARA INIBIR A PRODUçãO DE óXIDO NìTRICO E/OU CITOCINA EM MAMìFEROS, E PARA IMPEDIR OU TRATAR DOENçA CARDìACA, DOENçA AUTOIMUNE OU CHOQUE SéPTICO EM MAMìFEROS, E, PRó MEDICAMENTO". A presente invenção fornece um composto representado pela fórmula: em que R representa um grupo hidrocarboneto alifático que tenha opcionalmente substituintes, um grupo hidrocarboneto aromático que tenha opcionalmente substituintes, um grupo heterocíclico que tenha opcionalmente substituintes, um grupo representado pela fórmula: OR¹ (em que R¹ representa um átomo de hidrogênio ou um grupo hidrocarboneto alifático que tenha opcionalmente substituintes) ou um grupo representado pela fórmula: em que R^ 1b^ representa um átomo de hidrogênio ou um grupo hidrocarboneto alifático que tenha opcionalmente substituintes, R^ 1c^ é o mesmo como R^ 1b^ ou diferente dele, um átomo de hidrogênio ou um grupo hidrocarboneto alifático que tenha opcionalmente substituintes, R^ 0^ representa um átomo de hidrogênio ou um grupo hidrocarboneto alifático, ou R e R^ 0^ representam uma ligação um com o outro, Ar representa um grupo hidrocarboneto aromático que tenha opcionalmente substituintes, e n é um número inteiro de 1 a 4, ou um sal deste, que é um agente para prevenir ou tratar doenças tais como doença cardíaca, doença autoimune, choque séptico, etc.
BR9908610-7A 1998-03-09 1999-03-08 Composto, processo para produzir o mesmo, composição farmacêutica, uso do composto, processos par ainibir a produção de óxido nìtrico e/ou citocina em mamìferos, e para impedir ou tratar doença cardìaca, doença autoimune ou choque séptico em mamìferos, e, pró medicamentos BR9908610A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP5649298 1998-03-09
JP28436298 1998-10-06
PCT/JP1999/001103 WO1999046242A1 (en) 1998-03-09 1999-03-08 Cycloalkene derivatives, process for producing the same, and use

Publications (1)

Publication Number Publication Date
BR9908610A true BR9908610A (pt) 2000-12-05

Family

ID=26397446

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9908610-7A BR9908610A (pt) 1998-03-09 1999-03-08 Composto, processo para produzir o mesmo, composição farmacêutica, uso do composto, processos par ainibir a produção de óxido nìtrico e/ou citocina em mamìferos, e para impedir ou tratar doença cardìaca, doença autoimune ou choque séptico em mamìferos, e, pró medicamentos

Country Status (19)

Country Link
US (1) US6495604B1 (pt)
EP (2) EP1524263A1 (pt)
JP (2) JP3665712B2 (pt)
KR (4) KR20050071719A (pt)
CN (1) CN100432049C (pt)
AT (1) ATE287393T1 (pt)
AU (1) AU747521B2 (pt)
BR (1) BR9908610A (pt)
CA (1) CA2320467C (pt)
DE (1) DE69923300T2 (pt)
DK (1) DK1063228T5 (pt)
ES (1) ES2232114T3 (pt)
HU (1) HU230061B1 (pt)
ID (1) ID25649A (pt)
NO (1) NO326426B1 (pt)
NZ (1) NZ505874A (pt)
PT (1) PT1063228E (pt)
RU (1) RU2214398C2 (pt)
WO (1) WO1999046242A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2214398C2 (ru) 1998-03-09 2003-10-20 Такеда Кемикал Индастриз, Лтд. Производное циклоалкена, способ его получения (варианты), фармацевтическая композиция, способ ингибирования, способ профилактики или лечения
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
DE60045033D1 (de) 1999-08-06 2010-11-11 Takeda Pharmaceutical Substituierte aromatische ringverbindungen, verfahren zu ihrer herstellung und ihre anwendung
WO2001040498A1 (en) * 1999-11-29 2001-06-07 Takeda Chemical Industries, Ltd. Process for the production of optically active cyclohexene derivatives and intermediates therefor
JP4863553B2 (ja) * 2000-02-04 2012-01-25 武田薬品工業株式会社 安定な乳化組成物
KR100784752B1 (ko) * 2000-02-04 2007-12-13 다케다 야쿠힌 고교 가부시키가이샤 안정한 에멀젼 조성물
JP4922507B2 (ja) * 2000-08-10 2012-04-25 武田薬品工業株式会社 医薬組成物
EP1310248A4 (en) * 2000-08-10 2008-05-21 Takeda Pharmaceutical PHARMACEUTICAL COMPOSITION
AU2001295949A1 (en) 2000-10-18 2002-04-29 Takeda Chemical Industries Ltd. Process for preparation of optically active sulfonamides and intermediates for their synthesis
EP1348443A4 (en) * 2000-12-08 2005-07-06 Takeda Pharmaceutical COMBINED MEDICINES
US7579325B2 (en) 2001-03-21 2009-08-25 Eisai R & D Management Co., Ltd. Drugs containing reduced of vitamin B2
CA2456029C (en) * 2001-08-03 2010-12-07 Takeda Chemical Industries, Ltd. Stable emulsion composition
US20060058288A1 (en) * 2002-04-08 2006-03-16 Masayuki Ii Severe sepsis preventive therapeutic agent
ATE501128T1 (de) * 2003-12-03 2011-03-15 Boehringer Ingelheim Pharma 1,2,3-triazolamidderivate als inhibitoren der cytokinproduktion
MY147790A (en) * 2005-04-28 2013-01-31 Takeda Pharmaceutical Stable emulsion composition
KR101327610B1 (ko) * 2005-09-14 2013-11-12 다이이찌 산쿄 가부시키가이샤 치환 시클로알켄 유도체
EP1997902B1 (en) 2006-03-30 2013-09-18 Hiroshima University Screening method
US20090062355A1 (en) * 2006-04-20 2009-03-05 Takeda Pharmaceutical Company Limited Pharmaceutical Product
WO2007132825A1 (ja) 2006-05-15 2007-11-22 Takeda Pharmaceutical Company Limited 医薬
JPWO2008004673A1 (ja) 2006-07-07 2009-12-10 武田薬品工業株式会社 シクロアルケン誘導体、その製造法および用途
JP2008260760A (ja) * 2007-03-12 2008-10-30 Daiichi Sankyo Co Ltd 置換シクロアルケン誘導体を含有する医薬組成物
TWI481401B (zh) 2010-01-27 2015-04-21 Takeda Pharmaceutical 藥劑
JP5778161B2 (ja) 2010-09-24 2015-09-16 第一三共株式会社 置換シクロアルケン誘導体の結晶
AU2013286876B2 (en) * 2012-07-03 2017-04-20 Jay Pravda Methods for treating, diagnosing and/or monitoring progression of oxo associated states
US9364438B2 (en) 2012-09-26 2016-06-14 Takeda Pharmaceutical Company Limited Process for producing solid particles
CN107835800B (zh) 2015-05-08 2019-11-26 武田药品工业株式会社 环状化合物
WO2018047888A1 (ja) 2016-09-09 2018-03-15 武田薬品工業株式会社 環状化合物
WO2018156297A1 (en) * 2017-02-24 2018-08-30 Taiwanj Pharmaceuticals Co., Ltd Sulfonamide or amide compounds, compositions and methods for the prophylaxis and/or treatment of autoimmune, inflammation or infection related disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU665931B2 (en) 1990-11-06 1996-01-25 Nippon Shinyaku Co. Ltd. Lyophilized preparation and production thereof
AU653279B2 (en) * 1991-12-30 1994-09-22 Sanofi Novel 2-saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
FI963297L (fi) 1994-02-25 1996-10-18 Takeda Chemical Industries Ltd Antifungaalisia triatsolijohdannaisia sisältävät emulsiot
JPH08109165A (ja) * 1994-08-18 1996-04-30 Chugai Pharmaceut Co Ltd 一酸化窒素合成酵素阻害作用を有するアミノ酸誘導体
AU3230895A (en) * 1994-08-18 1996-03-14 Chugai Seiyaku Kabushiki Kaisha Amino acid derivative having nitrogen monoxide synthetase inhibitor activity
RU2214398C2 (ru) 1998-03-09 2003-10-20 Такеда Кемикал Индастриз, Лтд. Производное циклоалкена, способ его получения (варианты), фармацевтическая композиция, способ ингибирования, способ профилактики или лечения
KR100784752B1 (ko) 2000-02-04 2007-12-13 다케다 야쿠힌 고교 가부시키가이샤 안정한 에멀젼 조성물

Also Published As

Publication number Publication date
CN1291184A (zh) 2001-04-11
JP4342453B2 (ja) 2009-10-14
KR100577044B1 (ko) 2006-05-08
HU230061B1 (hu) 2015-06-29
WO1999046242A1 (en) 1999-09-16
EP1063228B1 (en) 2005-01-19
KR20050071719A (ko) 2005-07-07
DE69923300D1 (de) 2005-02-24
HK1031723A1 (en) 2001-06-22
EP1063228A4 (en) 2001-08-08
AU747521C (en) 1999-09-27
PT1063228E (pt) 2005-05-31
KR20010034555A (ko) 2001-04-25
NO20004485L (no) 2000-09-08
RU2214398C2 (ru) 2003-10-20
EP1063228A1 (en) 2000-12-27
KR100779889B1 (ko) 2007-11-28
NZ505874A (en) 2003-09-26
NO326426B1 (no) 2008-12-01
DK1063228T5 (da) 2009-06-15
AU2746499A (en) 1999-09-27
KR100492098B1 (ko) 2005-06-01
CA2320467A1 (en) 1999-09-16
US6495604B1 (en) 2002-12-17
JP2000178246A (ja) 2000-06-27
AU747521B2 (en) 2002-05-16
CA2320467C (en) 2010-05-04
DK1063228T3 (da) 2005-04-25
HUP0101192A3 (en) 2003-09-29
JP3665712B2 (ja) 2005-06-29
KR20050026075A (ko) 2005-03-14
KR20060017921A (ko) 2006-02-27
CN100432049C (zh) 2008-11-12
ES2232114T3 (es) 2005-05-16
HUP0101192A2 (hu) 2001-08-28
JP2005232168A (ja) 2005-09-02
EP1524263A1 (en) 2005-04-20
ATE287393T1 (de) 2005-02-15
DE69923300T2 (de) 2006-01-05
PL342826A1 (en) 2001-07-02
ID25649A (id) 2000-10-19
NO20004485D0 (no) 2000-09-08

Similar Documents

Publication Publication Date Title
BR9908610A (pt) Composto, processo para produzir o mesmo, composição farmacêutica, uso do composto, processos par ainibir a produção de óxido nìtrico e/ou citocina em mamìferos, e para impedir ou tratar doença cardìaca, doença autoimune ou choque séptico em mamìferos, e, pró medicamentos
DK0583421T3 (da) Substituerede dibenzoxazepinforbindelser, lægemidler og fremgangsmåder til anvendelse
PT1042291E (pt) Piridilalcano, alceno e alcino carboxamidas substituidas com arilo, uteis como agentes citostaticos e imunossupressores
PT652868E (pt) Inibidores da fosfodiesterase do amp ciclico
BR0213455A (pt) Composto, seu uso, composição farmacêutica, método para o tratamento ou prevenção de uma doença para a qual um receptor adenosina está relacionado, e método para promover a defecação
DK1060163T3 (da) Nye piperazinyl-substituerede pyridylalkan-, -alken og -alkyncarboxamider
MX9301214A (es) 1-alcoxi-2-(alcoxi-o cicloalquiloxi)-4-(ciclotioalquil o ciclotioalquenil-)benceno, proceso para su preparacion y composicion farmaceutica que lo co ntiene.
PT1042315E (pt) Piridilalcano alceno e alcino carboxamidas imido-substituidas ciclicas uteis como agentes citoestacticos e imunossupressores
HUP0103203A2 (hu) Azaadamantánszármazékok és ezeket tartalmazó gyógyszerkészítmények
BRPI0411221A (pt) composto, medicamento, métodos para inibir a produção de citocinas inflamatórias, e para a prevenção ou tratamento de doenças associadas com citocinas inflamatórias, método para o tratamento ou alìvio de febre, dor e/ou inflamação e, métodos para a prevenção ou tratamento de artrite reumatóide, de osteoartrite, de doença septicêmica, psorìase, doença de crohn, colite ulcerativa, diabete melito ou, hepatite
DK0696283T3 (da) 2-, 3,- 4,- 5,- 6,- 7,- 8,- 9,- og/eller 10 substituerede dibenzoxazepinforbindelser, lægemidler og anvendelser
DE69715891D1 (de) Pyrazolopyridinverbindung und seine pharmazeutische verwendung
DE69418744D1 (de) Verwendung von Pregnanderivaten zur Behandlung von Tumoren
BRPI0409069A (pt) compostos quìmicos
KR940702726A (ko) 치환된 퀴놀린-3-카르복시아미드 화합물의 용도 및 이를 이용한 다발성 경화증의 치료방법
DE69219124D1 (de) Fungizide verbindungen
BR9808672A (pt) Composto complexante, uso do mesmo, composição farmacêutica, e, processos para gerar uma imagem de um indivìduo animal animado humano ou não humano, para tratar o mesmo, e para preparar um complexo de um complexante
TW200510379A (en) 1, 4-disubstituted piperidine compounds, their preparation and use as medicaments
KR930703013A (ko) 항당뇨병제로서 유용한 신규한 글루코하이드롤라제 억제제
KR880009644A (ko) 궤양성 대장질환 치료용 약한 조성물
TH37815A (th) อนุพันธ์ 6,5-เฮทเทอโร-ไปไซคลิก ที่ถูกแทนที่
TH13819A (th) สารต้านไวรัส
ATE275576T1 (de) Ungesättigte 14,15-cyclopropano-androstane, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
TH18027A (th) อนุพันธ์ของอีพอกซิซัคฟินิคแอซิด
TH50173A (th) การใช้ 1-ไฮดรอกซี-2-ไพริโดนสำหรับการบำบัดการติดเชื้อที่ผิวหนัง

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

Free format text: NOME ALTERADO DE: TAKEDA CHEMICAL INDUSTRIES, LTD.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO DE ACORDO COM ( ART. 8O E ART. 11 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 18A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]